

CURRICULUM VITAE



CONTACT:

Name: Asst. Prof. Lazar Popović, MD, PhD

Licence number: 203866

Date of birth: 23.07.1979. in Novi Sad, Serbia

Address:

Home: Vojvode Šupljikca 9/31 , 21000 Novi Sad

Job: Clinic of medical oncology, Oncology Institute of Vojvodina, Put dr Goldmana 4, 21204 Sremska Kamenica, Serbia

Phone numbers:

Mobile: [+381638041910](tel:+381638041910)

Job: [+381214805569](tel:+381214805569), [+381214805420](tel:+381214805420)

e-mail: lazar.popovic@yahoo.com

EDUCATION:

1994-1998 Gymnasium “Jovan Jovanović Zmaj”, in Novi Sad, science and mathematics,

1998-2004 Medical faculty, in Novi Sad, **Medicine doctor** average 9,39/10.

2008-2011 Specialisation: Internal medicine

2013-2015 Subspecialisation: Oncology

2014 PhD “Significance of molecular markers expression in prognosis of diffuse large B-cell lymphoma treated with immunochemotherapy”

WORKING EXPERIENCE:

2004-2005 One year internship: Clinic for nephrology and clinical immunology, Clinical Centre of Vojvodina.

2005-2011 Medical doctor: Clinic for medical oncology, Oncology Institute of Vojvodina

2011-2015 Medical doctor, Internal medicine consultant: Clinic for medical oncology, Oncology Institute of Vojvodina

2015- Medical doctor, Internal medicine consultant, oncology subspecialist: Clinic for medical oncology, Oncology Institute of Vojvodina

2006-2014 Teaching assistant: Department of oncology, Medical faculty, Univeristy of Novi Sad

2014- Assistant Professor: Department of oncology, Medical faculty, Univeristy of Novi Sad

FOREIGN LANGUAGES:

English-fluently

German-beginner course (DAAD)

EDUCATION and EXPERIENCE:

2008 Professional education: Tenon Hospital, Paris, Medical Oncology and stem cell transplantation unit (Prof Lotz/ Prof Gligorov)

2016 ESMO Clinical Unit Visit Fellowship Grant: Oncology Institute Southern Switzerland, Lymphoma Unit, Breast Cancer Unit, Phase 1 Trials Unit (Prof Cavalli/Prof Ghielmini/Dr Zucca/Dr Pagani/Dr Stathis)

2006 Course “Apheresis on Cobe spectra”

2007 GCP course certificate

2012 GCP recerification Quintiles

2008 EBMT-Lymphoma working party training course

2009 EBMT-Infectious diseases working party training course

2011 EBMT-Medical statistics course

2012 Top 10 Teaching assistants at Medical Faculty of Novi Sad-Award of Students

MEMBERSHIPS:

BUON (Balkans Union of Oncology) member

ESMO (European Society for Medical Oncology) member

ESMO YO-National Representative

SLG (Serbian Lymphoma Study Group) member

SLD (Serbian Medical Society) member

AROME JUNIOR executive board member-research co-ordinator

AJOC (AROME Junior Oncologist Committee)-hematological malignancies co-coordinator

AROME (Association of Radiotherapy and Oncology in the Mediterranean Area) national board member

NOVI SAD ONCOLOGY CONGRESS 2009., 2010. and 2012. Head of Congress Secretariat

NOVI SAD ONCOLOGY CONGRESS 2014., 2015. Organizing committee member

ARCHIVE OF ONCOLOGY journal editor 2013-2015

ARCHIVE OF ONCOLOGY journal Editor-in-Chief 2015-

ONCOLOGY INSTITUTE OF VOJVODINA DRG IMPLEMENTATION TEAM 2013-2015

ONCOLOGY INSTITUTE OF VOJVODINA ACREDITATON TEAM (Medical oncology dept and Information technologies teams) 2014-2015

PROJECTS

“Maintaining Quality of Oncology Service in Autonomous Province of Vojvodina”- Educational Project, Minsitry of Health, Autonomous Province of Vojvodina 2015-2016

CLINICAL TRIALS:

PRINCIPLE INVESTIGATOR:

PHASE III: The Effect of Atezolizumab in Combination With Gemcitabine/Carboplatin and Gemcitabine/Carboplatin Alone in Participants With Untreated Locally Advanced or Metastatic Urothelial Carcinoma Who Are Ineligible for Cisplatin-based Therapy (Imvigor130)

PHASE I: TO-TAS-102-107 A Phase 1, Open-Label, Study to Evaluate the Safety, Tolerability, and Pharmacokinetics of TAS-102 in Patients with Advanced Solid Tumors and Varying Degrees of Renal Impairment

PHASE III: A Randomized, Double-blind, Multi-center, Multi-national Trial to Evaluate the Efficacy, Safety, and Immunogenicity of SAIT101 Versus Rituximab as a First-line Immunotherapy Treatment in

Patients with Low Tumor Burden Follicular Lymphoma

PHASE III: A Phase III, Open-Label, Multicenter, Randomized Study To Investigate The Efficacy And Safety Of MPDL3280A (Anti-PD-L1 Antibody, Atezolizumab) Compared With Chemotherapy In Patients With Locally Advanced Or Metastatic Urothelial Bladder Cancer After Failure With Platinum-Containing Chemotherapy

PHASE III: A phase 3, multicenter, randomized, double-blind, active control study to evaluate the safety and efficacy of IV pro-netupitant/palonosetron (260 mg/0.25 mg) combination for the prevention of chemotherapy-induced nausea and vomiting in repeated chemotherapy cycles in patients receiving highly emetogenic chemotherapy

PHASE IV: DIREGL07274-Metastatic Castrate Resistant Prostate Cancer-Serbian Registry

SUB-INVESTIGATOR:

PHASE I: Her-2 positive breast cancer; Aggressive Lymphoma.

PHASE II: Multiple myeloma, Diffuse Large B-Cell Lymphoma, Low Grade Lymphoma

PHASE III: Bladder Cancer-Immunotherapy (anti-PD-L1 adjuvant) , Multiple myeloma, Breast cancer (4 trials); Diffuse Large B-Cell Lymphoma; Follicular Lymphoma; Mantle Cell Lymphoma; Cancer and Coagulation (2 trials), Glioblastoma, Melanoma.

PHASE IV: Diffuse Large B-cell Lymphoma (2 trials), Follicular Lymphoma (2 trials), CLL, Mantle Cell Lymphoma

INTERESTS and KNOWLEDGE:

Breast cancer

Urological cancers

Lymphoma/CLL

Multiple myeloma

Biomarkers and signaling pathways in cancer

Target therapy

Autologous stem cell transplantation

Supportive care in cancer

Pharmacoeconomy and management

Clinical trials

MARITAL STATUS:

Married: Spouse Milica Popovic, medical doctor, internal medicine consultant (nephrology and clinical immunology dept.)

Two children: Tatjana born 2007, Stevan born 2011.

FREE TIME:

Sport: basketball, soccer, swimming

Music: playing drums

REFERENCES:

BOOKS:

1. Milic-Torres V, Popovic L, Vaz F, Penque D Proteomics in the Assessment of the Therapeutic Response of Antineoplastic Drugs: Strategies and Practical Applications in Ruef J and Sebastiao Rodrigues Casncer Drug Resistance: Overview and Methods. Methods in Molecular Biology vol 1395 DOI 10.1007/978-1-4939-3347-1_16 Springer Science+Business Media New York 2016
2. Cvetanovic A, Filipovic S, Vrbic S, Pejic I, Popovic L Side effects of cetuximab: rash in Madison R Hall. Head and neck cancer: epidemiology, management and treatment outcomes Nova Science Publishers 2015 ISBN: 978-1-63482-113-1
3. Popovic L., Grgic Z., Popovic M. "Melanoma during pregnancy" in Armstrong A. Advances in Malignant Melanoma: Clinical and Research Perspectives InTech 2011 ISBN 978-953-307-575-4
4. Lucic S, Lučić M, Peter A, Erak M, Popovic-Petrovic S, Kukić B, Popović L, Đuran B. PET/CT in diagnosis of cancer of unkown primary, Aktualnosti u u medicini i , stomatologiji i farmaciji: Zbornik radova :Medicinski fakultet Novi Sad 2010 (serbian)

PAPERS:

1. Popovic L, Popovic M Editorial Comment to Clinical Analysis Of Severe Psychiatric Disorders In Patients With Testicular Cancer: A Single-Center Experience Int J Urol (ahead of print) 2016
2. Popovic Dj, Popovic L Obesity and breast cancer - association even more relevant in males? Eur J Intern

3. Popovic L, Matovina-Brko G, Popovic M, Petrovic D, Cvetanovic A, Vukojevic J, Jovanovic D High dose chemotherapy with stem cell support in the treatment of testicular cancer World J Stem Cells 2015; 7(11): 1222-32
4. Cvetanovic A, Popovic L, Filipovic S, Trifunovic J, Zivkovic N, Matovina-Brko G, Kostic M; Vicko F, Kocic B, Kolarov-Bjelobrck I Young Age and Pathological Features Predict Breast Cancer Outcome-report from a Dual Institution Experience in Serbia J BUON 2015; 20(6): 1407-13
5. Jovanovic D, Petrovic D, Popovic L Target therapy for patients with Non-Hodgkin Lymphomas 3rd Congress of Hematologist Serbia 2015 PP24: 70-71
6. O. Markovic, L. Popović, D. Marisavljevic, J. Hajder R., Živković, N. Stanisavljevic, D. Jovanovic, B. Filipovic, D. Stanisavljevic, G. Matovina-Brko, T. Matkovic, , M. Todorović, D. Petrovic, B. Mihaljevic Prognostic Impact Analysis of absolute lymphocyte count (ALC) and absolute monocyte count (AMC) in patients with Diffuse Large B-Cell Lymphoma 3rd Congress of Hematologist Serbia 2015 OP23: 122
7. S. Popovic, B. Mihaljevic, N. Vlaisavljevic, L. Popovic, S. Salma, D. Agic, R. Milosevic, M. Smiljanic, S. Sretenovic, P. Djurdjevic, O. Markovic, J. Hajder, N. Govedarevic, D. Zivic, I. Savic, D. Jovanovic, N. Andjelkovic, T. Vukicevic, D. Marisavljevic Rituximab in the treatment of stage III and IV Follicular Lymphoma: Serbian Lymphoma Study Group Reflekt 1 results 3rd Congress of Hematologist Serbia 2015 OP25: 123
8. Popovic L, Matovina-Brko G. Anti-PD1/PD-L1 checkpoint inhibitors: a new frontier in cancer immunotherapy The second congress of the Serbian association for cancer research Proceedings book 2015 OP04: 14-17
9. Popovic L. Breast Cancer in very young woman X UMOS Conference Proceedings Book 2015
10. Popovic L. Target therapy in the treatment of Hodgkin Lymphoma VI NSOC Proceedings Book 2015
11. Popovic L, Jovanovic D, Knezevic-Usaj S, Nikin Z, Popovic Dj, Matovina-Brko G, Popovic M, Petrovic D The Expression of Molecular Markers As a Prognostic Factor of Diffuse Large B-Cell Lymphoma Treatment in Rituximab Era 1st ESH International Conference on New Concepts in B Cell Malignancies: From Molecular Pathogenesis to Personalized Treatment Abstr [2292 2014](#).
12. Popovic L., Jovanovic D., Petrovic D., Nikin Z., Matovina-Brko G., Trifunovic J., Kolarov-Bjelobrck I. Concurrent Chronic Lymphocytic Leukemia And Merkel Cell Carcinoma In Primary Skin Tumor And Metastatic Lymph Node Indian J Hematol Blood Transfus 2014 Sep;30(Suppl 1):422-4.
13. Popovic L, Trifunovic J, Pesic J, Matovina-Brko G, Kolarov-Bjelobrck I, Memisevic N, Jovanovic D Male Breast Cancer In The Era Of Modern Therapies: Serbian Single Centre Experience Report Breast J 2014 Apr 8. May;20(3):329-30
14. O. Markovic, L. Popović, D. Marisavljevic, D. Jovanovic, B. Filipovic, D. Stanisavljevic, G. Matovina-Brko, J. Hajder, T. Matkovic, R. Živković, N. Stanisavljevic, M. Todorović, D. Petrovic, B. Mihaljevic Comparison of prognostic impact of absolute lymphocyte count (ALC), absolute monocyte count (AMC), ALC/AMC prognostic score and ALC/AMC ratio in patients with diffuse large B cell lymphoma Eur J Intern Med 2014 Mar;25(3):296-302.
15. L. Popovic, O. Markovic, D. Jovanovic, D. Marisavljevic, D. Petrovic, B. Mihaljevic, Z. Nikin, T. Matkovic, G. Matovina-Brko, R. Zivkovic Differences in baseline characteristics and survival rates between GCB and non-GCB diffuse large B-cell lymphoma treated with rituximab based immunochemotherapy EJC Suppl 2013 ECCO-ESMO abstract 3629

16. L. Popovic, O. Markovic, D. Jovanovic, D. Marisavljevic, D. Petrovic, B. Mihaljevic, M. Popovic, T. Matkovic, G. Matovina-Brko, R. Zivkovic CD5-positive versus CD5-negative diffuse large B-cell lymphoma treated with immunochemotherapy: Is there a difference? EJC Suppl 2013 ECCO-ESMO abstract 3630
17. L. Popovic, Z. Nikin, D. Jovanovic, S. Knezevic-Usaj, M. Popovic, G. Matovina-Brko BAFF, TACI and BCMA receptors expression and their impact on survival of patients with diffuse large b-cell lymphoma EJC Suppl 2013 ECCO-ESMO abstract 3633
18. Matovina-Brko G., Ruzic M., Fabri M., Popovic L., Kolarov-Bjelobrk I., Trifunovic J., Petkovic D. Treatment of acute hepatitis C in breast cancer patient J chemother 2014 Jun;26(3):180-3
19. Matovina-Brko G, Nikolin B, Popovic L, Nikin Z, Jovanovic D, Popovic-Petrovic S. Paratesticular rhabdomyosarcoma of a young adult: a case report with review of the literature. Contemporary Oncology 2013 (ahead of print)
20. Markovic O, Popovic L, Marisavljevic D, Jovanovic D, Mihaljevic B, Stanisavljevic D, Hajder J, Zivkovic R, Petrovic D, Stanisavljevic N, Matovina-Brko G, Todorovic M, Bila J Prognostic Significance Of Low Lymphocytes Count In The Patients With Diffuse Large B Cell Lymphoma (DLBCL) Haematologica 2013 (EHA Abstract)
21. B. Mihaljevic, D. Jovanovic, N. Andjelkovic, S. Popovic, T. Vukicevic, B. Andjelic, L. Popovic, M. Todorovic, N. Vlasisavljevic, A. Sretenovic, P. Djurdjevic, S. Sretenovic, S. Jankovic, O. Markovic, G. Marjanovic, S. Vrbic, J. Hajder, D. Zivic. Maximizing therapeutic benefit of rituximab for Relapsed/resistant follicular lymphoma: 2 years maintenance therapy results Hematol Oncol 2013; 31 (suppl. 1): 221
22. Lučić S, Peter A, Jovanović D, Popović L, Lučić A M, Kozarski D, Spirovski M Role Of 18f-Fdg Pet/Ct In Patients With Follicular Lymphoma 2nd Balkan Congress of Nuclear Medicine, 2013.
23. Popovic L, Popovic M, Jelic M Resistance to rituximab treatment: mechanisms and therapeutic interventions. Med Danas 2013 (Ahead of print) (serbian)
24. Popovic L., Jovanovic D., Popovic Dj. CD30-the head of the TNF family...or the successful story of brentuximab-vedotin Arch Oncol 2013; 21 (1): 17-19
25. Jelic M, Jovanovic D, Popovic L, Striber-Devaja D Monoclonal antibodies at the Oncology Institute of Vojvodina-5 year expenditure Arch Oncol 2012; 20(3-4): 53-6
26. Popovic Dj, Popovic L, Stokic E, Tomic-Naglic D, Mitrovic M, Kovačev-Zavisic B Influence of metformin therapy on breast cancer incidence and prognosis. Arch Oncol 2012; 20(3-4): 62-9
27. L. Popovic, D. Jovanovic, D. Donat, D. Petrovic, T. Roganovic, J.-P. Lotz High dose chemotherapy with autologous stem cell transplantation for the patients with germ-cell cancer J BUON 2013; 18(1): 289-295
28. [Lucic S, Peter A, Jovanovic D, Popovic L, Petrovic D, Lucic M 18F-FDG PET/CT diagnostic value in the temporal follow-up of lymphoma patients. Eur J Nucl Med Mol Imaging 2012; 39: S584](#)
29. [Petrovic D., Jovanovic D., Popovic L. Risk models for predicting chemotherapy-induced neutropenia in patients with solid tumors and malignant lymphoma Haematologica 2012 \(EHA](#)

2012; abstr 1784)

30. B Mihaljevic ,D Antic ,B Andjelic ,L Popovic ,D Agic ,V Nikolic ,S Sretenovic ,V Vukovic New prognostic model in follicular non-Hodgkin lymphoma treated with rituximab chop: association of comorbidities with overall survival Haematologica 2012 (EHA 2012 abstr 1698)

31. B Andjelic ,D Antic ,V Nikolic ,L Popovic ,V Vukovic ,B Mihaljevic The impact of comorbidity burden on the overall survival in patients with diffuse large B-cell lymphoma Haematologica 2012 (EHA 2012 abstr 1701)

32. Petrovic-Popovic S, Tomic S, Nedeljkovic M, Popovic L, Matovina G Early rehabilitation in patients with breast carcinoma Vojnosanit Pregl. 2013 Apr;70(4):407-10

33. Popovic-Petrovic S, Nedeljkovic M, Popovic L, Petrovic V Secondary Lymphedema of the arm in breast carcinoma at the Oncology institute of Vojvodina: 2001 – 2006 Healthmed 2011; 5(6): 1719-25

34. Popovic L. , Jovanovic D., Petrovic D., Sundji A., Petrovic N., Roganovic T., Kukic B. Prognostic factors in the treatment of primary extranodal diffuse large B-cell lymphoma with rituximab-based immunochemotherapy Haematologica 2011; 96 (Supp 2):560

35. B. Mihaljevic, D. Antic, B. Andjelic, M. Todorovic, T. Vukicevic, V. Nikolic, I. Pejic, I. Petkovic, S. Popovic, L. Popovic, N. Andjelkovic, S. Sretenovic, M. Smiljenic, O. Markovic, J. Knezevic Prognostic significance of the Ki-67 index in diffuse large B-cell lymphoma patients treated with rituximab plus CHOP-experience of Serbian Lymphoma Study group Haematologica 2011; 96 (Supp 2): 575-6

36. B. Mihaljevic, D. Antic, B. Andjelic, T. Vukicevic, V. Nikolic, I. Pejic, I. Petkovic, S. Popovic, L. Popovic, N. Andjelkovic, S. Sretenovic, D. Lekovic, M. Smiljanic, O. Markovic, V. Knezevic, V. Kecman Characteristics of 917 Non-Hodgkin's lymphoma patients in Serbia according to the WHO classification of lymphoid neoplasms-LIRA national register-based study Ann Oncol 2011; 22 (Supp 4): iv204

37. B. Mihaljevic, B. Andjelic, D. Antic, M. Todorovic, T. Vukicevic, V. Nikolic, I. Pejic, I. Petkovic, S. Popovic, I. Savic., L. Popovic, N. Andjelkovic, S. Sretenovic, J. Knezevic, V. Kecman Diffuse large B-cell lymphoma: germinal center vs non germinal center-treatment response on immunochemotherapy. Serbian Lymphoma Study group Ann Oncol 2011; 22 (Supp 4):iv224-5

38. Jovanovic D., Popovic L. et al Role of PET/CT in diagnosis and treatment of Lymphoma Haematology Congress of Bosnia and Herzegovina, Sarajevo, May 2011.

39. Jovanovic Da, Petrovic D., Popovic L., Bjelobrk-Kolarov I., Jovanovic Du. Thromboprophylaxis in hospitalized cancer patients Hematol Rep 2011; 3(Supp 1): 19

40. Stankov K., Bogdanovic G., Kojic V, Stankov S., Jovic N., Popovic L., Popovic S. Expression analysis of genes involved in epigenetic regulation and apoptosis in human malignant cell lines treated by 5-Azacytidine J BUON 2011;16 (1):116-122

41. L. Popovic, D. Jovanovic, D. Donat, D. Petrovic, T. Roganovic, J.-P. Lotz High-dose chemotherapy with autologous stem cell support for the heavily pretreated patients with germ cell tumours: a Serbian single-centre first-experience report Bone Marrow Transpl 2011; 46(Supp 1): 385

42. L. Popovic, D. Jovanovic, D. Petrovic, A. Sundji, N. Petrovic, T. Roganovic, B. Kukic

Treatment of Primary Extranodal Diffuse Large B-cell Lymphoma with Immunochemotherapy- Our Experience 2nd Serbian Hematology Congress/6th Balkan Day of Haematology Abstract Book Nov 2011:172.

43. L. Popovic, D. Jovanovic, D. Petrovic, N. Petrovic, A. Sundji, T. Roganovic, G. Matovina-Brko Significance of Standard Prognostic Scores (IPI and R-IPI) in Prognosis of Diffuse Large B-cell Lymphoma Patients treated with Immunochemotherapy 2nd Serbian Hematology Congress/6th Balkan Day of Haematology Abstract Book Nov 2011:173.

44. B. Mihaljevic, D. Jovanovic, N. Andjelkovic, S. Popovic, T. Vukicevic, B. Andjelic, L. Popovic, M. Todorovic, N. Vlasisavljevic, A. Sretenovic, P. Djurdjevic, S. Sretenovic, S. Jankovic, O. Markovic, G. Marjanovic, S. Vrbic, J. Hajder, D. Zivic Rituximab in combination with Chemotherapy in Patients with Relapsed/Refractory Follicular NHL-Serbian Lymphoma Study Group Experience. 2nd Serbian Hematology Congress/6th Balkan Day of Haematology Abstract Book Nov 2011:166.

45. D. Agic, I. Savic, S. Popovic, I. Percic, V. Kvrgetic, B. Sekulic, B. Andjelic, D. Antic, L. Popovic, D. Jovanovic, T. Vukicevic, N. Andjelkovic, S. Vrbic, V. Nikolic, S. Sretenovic, B. Mihaljevic Spread of Diffuse Large B-cell Lymphoma in Serbian Patients 2nd Serbian Hematology Congress/6th Balkan Day of Haematology Abstract Book Nov 2011:20-22

46. V. Nikolic, D. Antic, B. Andjelic, M. Todorovic, T. Vukicevic, I. Pejic, I. Petkovic, S. Popovic, L. Popovic, N. Andjelkovic, S. Sretenovic, O. Markovic, J. Knezevic, B. Mihaljevic Prognostic significance of Ki-67 index in Patients with Diffuse Large B-cell Lymphoma treated with Rituximab plus CHOP-Serbian Lymphoma Study Group Experience 2nd Serbian Hematology Congress/6th Balkan Day of Haematology Abstract Book Nov 2011:23-25

47. S. Sretenovic, N. Andjelkovic, D. Antic, B. Andjelic, T. Vukicevic, V. Nikolic, S. Popovic, L. Popovic, O. Markovic, J. Knezevic, B. Mihaljevic Prospective non-selective Study of patients with Lymphoproliferative Neoplasms in Serbia-LIRA National Register 2nd Serbian Hematology Congress/6th Balkan Day of Haematology Abstract Book Nov 2011:26-29.

48. B. Andjelic, D. Antic, V. Nikolic, L. Popovic, V. Vukovic, B. Mihaljevic Prognostic Significance of Comorbidity Indices in Diffuse Large B-Cell Lymphoma 2nd Serbian Hematology Congress/6th Balkan Day of Haematology Abstract Book Nov 2011:34-36.

49. B. Mihaljevic, D. Antic, B. Andjelic, D. Lekovic, D. Jovanovic, L. Popovic, T. Vukicevic, I. Pejic, N. Andjelkovic, P. Djurdjevic, O. Markovic High ki-67 protein expression as prognostic factor in diffuse large B-cell lymphoma – experience of Serbian Lymphoma study Group Abstract 416; International Society of Haematology Congress, Jerusalem, Israel 2010.

50. Popovic L, Jovanovic D., Matovina-Brko G., Petrovic D., Nikin Z, Roganovic T. Primary diffuse large B-cell lymphoma of the breast Arch Oncol 2009; 17 (3-4): 80-2

51. Grgic Z, Oros A, Rasic D, Popovic L, Popovic M Ocular malignant melanoma in pregnancy: is a happy ending possible? Arch Oncol 2009; 17 (3-4): 83-5

52. Popovic L, Jovanovic D, Petrovic D, Matovina G, Roganovic T. ALK-negative large cells lymphoma in skeletal muscle-case report. Medicina Danas 2009; 8(7-9): 249-54. (serbian)

53. Stankov K, Tauszig-Delamasure S, Bogdanovic G, Popovic L, Stankov S, Sylvisus N, Popovic S, Mehlen P. [Expression of the genes involved in apoptosis, proliferation and endoplasmic reticulum stress in ionomycin/PMA treated Jurkat cells](#) EJC Supplements (2008), 6(12): 89-90.

54. Stankov, K; Bogdanovic, G; Popovic L; Popovic, S; Tauszig-Delamasure, S; Mehlen, P; Sylvius, N Expression of c-kit/SCF tyrosine kinase signaling pathway and apoptotic genes in ionomycin/PMA treated Jurkat cells EJC Supplements (2008), 6(9): 147-147
55. Andrijevic LJ, Aleksic L, Baltic M, Popovic L, Jovanovic D, Petrovic D, Matovina G. Enumeration of haematopoietic CD34+ stem cells by flowcytometry. Balkan flow users meeting Rovinj Croatia 2008.
56. Popovic L. Rituximab maintenance therapy in follicular lymphoma Arch Oncol 2008;16(1-2): 23. 0
57. Popovic L. Anti-CD20 MAB(s)..., but not...THERA. Arch Oncol 2008; 16(1-2):23-24.
58. Popovic L., Jovanovic D., Petrovic D., Matovina G., Roganovic T. „Rituximab in combination with chemotherapy in treatment of diffuse large B-cell lymphoma: our experience“ Abstr.33 Bilt. Hematol 2007; 35(3): 86-100 (serbian)
59. Popovic L., Jovanovic D., Petrovic D., Matovina G., Roganovic T. „Breast involving lymphoma: report of four cases“ Abstr. 35 Bilt. Hematol 2007; 35(3): 86-100 (serbian)
60. Popovic L., Jovanovic D., Petrovic D., Matovina G., Roganovic T. „ALK-negative anaplastic large T-cell lymphoma in a muscle: case report and review of literature“ Abstr. 44 Bilt. Hematol 2007; 35(3): 86-100 (serbian)
61. Matovina G., Jovanovic D., Fabri M., Petrovic D., Popovic L., Roganovic T. „Heapatitis B viral infection reactivation during induction lymphoma therapy: report of two cases“ Abstrakt br. 54 Bilt. Hematol 2007; 35(3): 86-100 (serbian)
62. Tešanovic S. Popovic L.: « Efficacy of lower dose capecitabine in metastatic breast cancer» Sr. Kamenica 2006. (serbian)
63. Popovic L. «Quality of life in different insuline therapy regimen (CIT, MSII)» Limsc Leiden Holland 2005.